ATS 2017Spiriva® Respimat® improves breathing for people with asthma regardless of BMI or allergic status
Boehringer Ingelheim today announced new analyses that provide further evidence that adding tiotropium Respimat® (Spiriva® Respimat®) improved breathing across diverse patient populations who experience uncontrolled asthma symptoms despite the use of another daily maintenance therapy in the Phase III clinical development program. These data analyses were presented today at the American Thoracic Society International (ATS) Conference in Washington, D.C., USA.
“These new analyses add to the wealth of evidence from the large-scale UniTinA-asthma® clinical trial programme to show tiotropium Respimat® is effective in a broad range of patients with symptomatic asthma, including those with allergies or a high BMI, which may make their symptoms more difficult to manage,” said Jennifer Haddon, Global Medical Advisor Respiratory at Boehringer Ingelheim. “Of those people already on asthma treatment, almost half still experience symptoms, highlighting the need for better management. These data underline the commitment of Boehringer Ingelheim to advancing our understanding of which patients may benefit most from our medicines.”
People with allergic asthma – the most common form of the condition – can experience inflammation and a tightening of the airways when exposed to common allergens. These patients may need other options that complement their existing therapy.
For further information, please see the press release distributed by Boehringer Ingelheim US.
* Note: Spiriva® Respimat® is currently NOT APPROVED for use in children and adolescents under 18 years of age in the EU and a number of other countries. Spiriva ® Respimat® has been approved for use in asthma in over 75 countries, including in the EU, U.S. and Japan. The label and doses vary by country. Please refer to the local product information.
Asthma is one of the most common conditions in childhood.4 There are fewer treatment options in paediatric asthma than in adult asthma.5
Asthma is not conquered. Almost 1 in 2 patients remain symptomatic despite their current maintenance therapies (usually ICS/LABA).6, 7, 8 These symptoms have a detrimental effect on their work, education, sleep, social life and relationships.9 Additionally, symptoms increase their risk of potentially fatal asthma attacks in the next few weeks by up to six times.10
For more information please see the latest infographic.
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
For references and notes to editors, please visit:
Media + PR
Phone: +49 6132 77 182085
Mobile: +49 151 44061760
Fax: +49 6132 77 6601
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AstraZeneca and Chi-Med’s Savolitinib Shows Encouraging Clinical Activity in 2nd-Line EGFR Mutation-positive Lung Cancer with MET-amplification16.10.2017 22:00 | Pressemelding
AstraZeneca and its partner Chi-Med today presented preliminary safety and clinical activity of savolitinib when given in combination with either Tagrisso (osimertinib) or Iressa (gefitinib) in two Phase Ib trials conducted in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) with MET-amplification who had progressed following 1st-line treatment with an EGFR inhibitor.1,2 In both trials, the addition of savolitinib (600mg, once daily), an investigational selective inhibitor of c-MET (mesenchymal epithelial transition factor) receptor tyrosine kinase, to osimertinib (80mg, once daily) or gefitinib (250mg, once daily) demonstrated preliminary anti-tumour activity. The data were shared in two oral presentations at the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan, 15-18 Oc
Orlando Melbourne Int’l (MLB) Lands Largest FAA Grant in Its History16.10.2017 21:34 | Pressemelding
When Air Force One landed at Orlando Melbourne International Airport (MLB) in February, Airport Executive Director Greg Donovan took advantage of the opportunity and advised the president of the United States that his 747-200 just landed on a commercial runway officially rated ‘poor’ in aviation terms. That’s going to change, thanks to an $18,132,588 FAA grant announced by U.S. Secretary of Transportation Elaine Chao today. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171016006292/en/ Greg Donovan, A.A.E. (Photo: Business Wire) “We asked for, and received, tremendous support from the Florida congressional delegation,” said Jack L. Ryals, chairman of the Melbourne Airport Authority. “We are deeply grateful to Congressman Posey, Senator Nelson and Senator Rubio for their advocacy on this critic
Colombia Selects IDEMIA to Upgrade Its Identification and Civil Registry Platform16.10.2017 14:34 | Pressemelding
IDEMIA, the global leader in trusted identities for an increasingly digital world, has been selected by the National Civil Registry of Colombia (Registraduría Nacional del Estado Civil de Colombia – RNEC 1 ) to update the identification and civil registry platform. This platform is the trusted repository of citizens’ biometric and alphanumeric data and ensures the uniqueness of identities. IDEMIA (formerly known as OT-Morpho) has worked with the RNEC since the beginning of this project and has constantly supported the successive improvements of the solution. In 2017, when in need to strengthen the platform in order to offer new services to the government and to the population while maintaining a high level of security and satisfaction of the users, RNEC decided to pursue its partnership with IDEMIA. Through this new contract, IDEMIA will e
ATB Financial Goes-Live on Murex’s SaaS Solution16.10.2017 14:00 | Pressemelding
Sibos - Murex, a global leader in trading, risk management and processing solutions, is pleased to announce the successful launch of the MX.3 SaaS solution at ATB Financial. MUREX SaaS is a managed services offering for the MX.3 platform, encompassing infrastructure and application management. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171016005092/en/ ATB pursued this initiative in order to create a simple yet comprehensive foreign exchange experience for their customers. In addition to the customer benefit, ATB was also able to rationalize their IT landscape, broaden the scope of financial instruments they provide on their digital platform, and prepare for a large volume increase in their trading activities. Due to the strength of the solution’s risk management capabilities, extensive asset class coverage, and the ra
Leave a review on print24.com and win a VW up!16.10.2017 13:59 | Pressemelding
The online print shop UNITEDPRINT SE, owner of renowned brands including print24.com, is asking its customers for their opinions on the company’s products and services. In return for their views, customers will receive vouchers and be entered into a prize draw. The online print shop is offering one voucher for every review submitted across various portals. The vouchers – worth up to €25.00 and valid until 31 March 2018 – will be subject to a minimum order amount (product price inc. VAT, not including delivery) of €250.00 per voucher. All reviews received up to 31 December 2017 will be eligible, regardless of length and content. You can learn more about the review campaign at https://print24.com/rate/ But not only that, print24.com is also giving every reviewer the chance to win a brand-new VW up! Ali Jason Bazooband, Managing Director for Innovation/Marketing at print24.com,
Bentley Systems Announces Winners of 2017 Be Inspired Awards16.10.2017 13:52 | Pressemelding
The Year in Infrastructure 2017 Conference – Bentley Systems, Incorporated, a leading global provider of comprehensive software solutions for advancing infrastructure, has announced the winners of the 2017 Be Inspired Awards. The annual awards program honors the extraordinary work of Bentley users advancing the world’s infrastructure. At a ceremony and gala at their Year in Infrastructure 2017 Conference, Bentley acknowledged 17 Be Inspired Awards winners and six Special Recognition Awards winners. The Year in Infrastructure Conference is Bentley’s annual global gathering of leading professionals in the world of infrastructure design, construction, and operations. In addition to thought-provoking keynotes, technology demonstrations, industry forums, and panel discussions, the agenda included presentations by finalists in the Be Inspired Awards program, culminating in the selection of t
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom